Background and Aim: Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most common pain relief medications, but the risk of hemorrhagic stroke in patients taking these medications is unclear. In this study, our aim was to systematically review, synthesize, and critique the epidemiological studies that evaluate the association between NSAIDs and hemorrhagic stroke risk. We therefore assessed the current state of knowledge, filling the gaps in our existing concern, and make a recommendation for future research. Methods: We searched for articles in PubMed, EMBASE, Scopus, and Web of Science between January 1, 1990, and July 30, 2017, which reported on the association between the use of NSAIDs and hemorrhagic stroke. The search was limited to studies published in English. The quality of the included studies was assessed in accordance with the Cochrane guidelines and the Newcastle-Ottawa criteria. Summary risk ratios (RRs) with 95% CI were pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 15 out of the 785 unique abstracts for full-text review using our selection criteria, and 13 out of these 15 studies met all of our inclusion criteria. The overall pooled RR of hemorrhagic stroke was 1.332 (95% CI 1.105–1.605, p = 0.003) for the random effect model. In the subgroup analysis, a significant risk was observed among meloxicam, diclofenac, and indomethacin users (RR 1.48; 95% CI 1.149–1.912, RR 1.392; 95% CI 1.107–1.751, and RR 1.363; 95% CI 1.088–1.706). In addition, a greater risk was found in studies from Asia (RR 1.490, 95% CI 1.226–1.811) followed by Europe (RR 1.393, 95% CI 1.104–1.757) and Australia (RR 1.361, 95% CI 0.755–2.452). Conclusion: Our results indicated that the use of NSAIDs is significantly associated with a higher risk of developing hemorrhagic stroke. These results should be interpreted with caution because they may be confounded owing to the observational design of the individual studies. Nevertheless, we recommend that NSAIDs should be used judiciously, and their efficacy and safety should be monitored proactively.

1.
Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, Barker-Collo S, Moran AE, Sacco RL, Truelsen T, et al: Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD 2013 study. Neuroepidemiology 2015; 45: 161–176.
2.
Bonzini M, Ferrario MM, Bertù L, Bono G, Vidale S, Veronesi G, Chambless L, Cesana GC: Temporal trends in ischemic and hemorrhagic strokes in Northern Italy: results from the Cardiovascular Monitoring Unit in Northern Italy population-based register, 1998–2004. Neuroepidemiology 2012; 39: 35–42.
3.
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, et al: Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245–255.
4.
Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013; 127:e6–e245.
5.
Lee KR, Bae JH, Hwang IC, Kim KK, Suh HS, Ko KD: Effect of influenza vaccination on risk of stroke: a systematic review and meta-analysis. Neuroepidemiology 2017; 48: 103–110.
6.
Algra AM, Klijn CJ, Helmerhorst FM, Algra A, Rinkel GJ: Female risk factors for subarachnoid hemorrhage: a systematic review. Neurology 2012; 79: 1230–1236.
7.
Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M: Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013; 27: 35–45.
8.
Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH, Ritz B: Non-steroidal anti-inflammatory drug use and the risk of Parkinson’s disease. Neuroepidemiology 2011; 36: 155–161.
9.
Group ADAPT Research: Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1:e33.
10.
Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R: Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27: 411–420.
11.
Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.
12.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
13.
Islam MM, Yang HC, Nguyen PA, Poly TN, Huang CW, Kekade S, Khalfan AM, Debnath T, Li YJ, Abdul SS: Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet 2017; 296: 1043–1053.
14.
Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen PA, Poly TN, Masud JH, Li YJ, Shabbir SA: Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 2016; 47: 181–191.
15.
Yang HC, Nguyen PAA, Islam M, Huang CW, Poly TN, Iqbal U, Li YJ: Gout drugs use and risk of cancer: a case-control study. Joint Bone Spine 2018, Epub ahead of print.
16.
Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.
17.
Hsu PS, Lin HH, Li CR, Chung WS: Increased risk of stroke in patients with osteoarthritis: a population-based cohort study. Osteoarthritis Cartilage 2017; 25: 1026–1031.
18.
Bak S, Andersen M, Tsiropoulos I, García Rodríguez LA, Hallas J, Christensen K, Gaist D: Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke 2003; 34: 379–386.
19.
Johnsen SP, Pedersen L, Friis S, Blot WJ, McLaughlin JK, Olsen JH, Sørensen HT: Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Stroke 2003; 34: 387–391.
20.
Thrift AG, McNeil JJ, Forbes A, Donnan GA: Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ 1999; 318: 759–764.
21.
Choi NK, Park BJ, Jeong SW, Yu KH, Yoon BW: Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. Stroke 2008; 39: 845–849.
22.
Chuang SY, Yu Y, Sheu WH, Tsai YT, Liu X, Hsiung CA, Tsai HJ: Association of short-term use of nonsteroidal anti-inflammatory drugs with stroke in patients with hypertension. Stroke 2015; 46: 996–1003.
23.
Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS: Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010; 41: 1884–1890.
24.
Lapi F, Piccinni C, Simonetti M, Levi M, Lora Aprile P, Cricelli I, Cricelli C, Fanelli A: Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016; 11: 49–59.
25.
Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL: Stroke risk and NSAIDs: an Australian population-based study. Med J Aust 2011; 195: 525–529.
26.
Fosbøl EL, Olsen AM, Olesen JB, Andersson C, Kober L, Torp-Pedersen C, Gislason GH: Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. Intern J Stroke 2014; 9: 943–945.
27.
Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH: Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168: 1219–1224.
28.
Mangoni AA, Woodman RJ, Gilbert AL, Knights KM: Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 2010; 19: 490–498.
29.
Roumie CL, Mitchel EF Jr, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR: Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39: 2037–2045.
30.
Islam MM, Iqbal U, Walther BA, Nguyen PA, Li YJ, Dubey NK, Poly TN, Masud JHB, Atique S, Syed-Abdul S: Gender-based personalized pharmacotherapy: a systematic review. Arch Gynecol Obstet 2017; 295: 1305–1317.
31.
Higgins JP, Green S: Cochrane Handbook for Systematic Reviews of Interventions. Chichester, John Wiley & Sons, 2011.
32.
Poly TN, Islam MM, Walther BA, Yang HC, Nguyen PA, Huang CW, Shabbir SA, Li YJ: Exploring the association between statin use and the risk of Parkinson’s disease: a meta-analysis of observational studies. Neuroepidemiology 2017; 49: 142–151.
33.
Ungprasert P, Matteson EL, Thongprayoon C: Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hemorrhagic stroke: a systematic review and meta-analysis of observational studies. Stroke 2016; 47: 356–364.
34.
Lee JG, Lee KB, Jang IM, Roh H, Ahn MY, Woo HY, Hwang HW: Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. Cerebrovasc Dis 2013; 35: 53–59.
35.
Ovbiagele B, Schwamm LH, Smith EE, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC: Hospitalized hemorrhagic stroke patients with renal insufficiency: clinical characteristics, care patterns, and outcomes. J Stroke Cerebrovasc Dis 2014; 23: 2265–2273.
36.
Party ISW: National clinical guideline for stroke, London: Royal College of Physicians, 2012.
37.
Wang Y, Rudd AG, Wolfe CD: Age and ethnic disparities in incidence of stroke over time: the South London Stroke Register. Stroke 2013; 44: 3298–3304.
38.
Adamson J, Beswick A, Ebrahim S: Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis 2004; 13: 171–177.
39.
Rowe FJ, Walker M, Rockliffe J, Pollock A, Noonan C, Howard C, Glendinning R, Currie J: Care provision and unmet need for post stroke visual impairment. Final report 2013. www.stroke.org.uk/sites/default/files/final_report_unmet_need_2013.pdf?
40.
Dickey L, Kagan A, Lindsay MP, Fang J, Rowland A, Black S: Incidence and profile of inpatient stroke-induced aphasia in Ontario, Canada. Arch Phys Med Rehabil 2010; 91: 196–202.
41.
Engelter ST, Gostynski M, Papa S, Frei M, Born C, Ajdacic-Gross V, Gutzwiller F, Lyrer PA: Epidemiology of aphasia attributable to first ischemic stroke: incidence, severity, fluency, etiology, and thrombolysis. Stroke 2006; 37: 1379–1384.
42.
Lawrence ES, Coshall C, Dundas R, Stewart J, Rudd AG, Howard R, Wolfe CD: Estimates of the prevalence of acute stroke impairments and disability in a multiethnic population. Stroke 2001; 32: 1279–1284.
43.
Yaxley J, Litfin T: Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. Ren Fail 2016; 38: 1328–1334.
44.
De Caterina R, Ruigómez A, Rodríguez LA: Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med 2010; 170: 1450–1455.
45.
Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron J, Bombardier C, Cannon C, Farkouh M, FitzGerald G: Vascular and Upper Gastrointestinal Effects of Non-Steroidal Anti-Inflammatory Drugs: Meta-Analyses of Individual Participant Data from Randomised Trials. Lancet 2013; 382: 769–779.
46.
Latimer N, Lord J, Grant RL, O’Mahony R, Dickson J, Conaghan PG: Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for -people with osteoarthritis. BMJ 2009; 339: b2538.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.